×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AXGN – axogen, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AXGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/5
12:14 pm
axgn
AxoGen (NASDAQ:AXGN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
AxoGen (NASDAQ:AXGN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/5
08:43 am
axgn
AxoGen (NASDAQ:AXGN) was given a new $37.00 price target on by analysts at Canaccord Genuity Group Inc..
Low
Report
AxoGen (NASDAQ:AXGN) was given a new $37.00 price target on by analysts at Canaccord Genuity Group Inc..
12/4
03:07 pm
axgn
AxoGen (NASDAQ:AXGN) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
Low
Report
AxoGen (NASDAQ:AXGN) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
12/4
09:08 am
axgn
AxoGen (NASDAQ:AXGN) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
Medium
Report
AxoGen (NASDAQ:AXGN) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
12/4
08:04 am
axgn
AxoGen (NASDAQ:AXGN) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
High
Report
AxoGen (NASDAQ:AXGN) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
12/3
11:41 pm
axgn
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx) [Yahoo! Finance]
Medium
Report
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx) [Yahoo! Finance]
12/3
08:01 pm
axgn
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
Medium
Report
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
12/3
07:57 am
axgn
AxoGen (NASDAQ:AXGN) was upgraded by analysts at Mizuho to a "strong-buy" rating.
Low
Report
AxoGen (NASDAQ:AXGN) was upgraded by analysts at Mizuho to a "strong-buy" rating.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
12/4
03:07 pm
Reiterates
Outperform
Outperform
Raymond James Financial, Inc.
Low
Report
-1.3%
Date
Time
Symbol
Headline
Impact
12/16
05:04 pm
axgn
Form 144 Axogen, Inc. Filed by: Wendell Amy McBride
Low
Report
Form 144 Axogen, Inc. Filed by: Wendell Amy McBride
12/16
04:27 pm
axgn
Form 144 Axogen, Inc. Filed by: Weiler Kathy Johnson
Low
Report
Form 144 Axogen, Inc. Filed by: Weiler Kathy Johnson
12/15
05:38 pm
axgn
Form 144 Axogen, Inc. Filed by: Hartley Lindsey Marie
Medium
Report
Form 144 Axogen, Inc. Filed by: Hartley Lindsey Marie
12/12
04:06 pm
axgn
Form 4 Axogen, Inc. For: Dec 11 Filed by: Began Marc A
Low
Report
Form 4 Axogen, Inc. For: Dec 11 Filed by: Began Marc A
12/12
04:06 pm
axgn
Form 4 Axogen, Inc. For: Dec 10 Filed by: DALE MICHAEL D
Low
Report
Form 4 Axogen, Inc. For: Dec 10 Filed by: DALE MICHAEL D
12/11
04:09 pm
axgn
Form 144 Axogen, Inc. Filed by: Began Marc A
Low
Report
Form 144 Axogen, Inc. Filed by: Began Marc A
12/10
05:21 pm
axgn
Form 4 Axogen, Inc. For: Dec 09 Filed by: TYNDALL JOSEPH A.
Low
Report
Form 4 Axogen, Inc. For: Dec 09 Filed by: TYNDALL JOSEPH A.
12/10
05:21 pm
axgn
Form 4 Axogen, Inc. For: Dec 09 Filed by: DALE MICHAEL D
Low
Report
Form 4 Axogen, Inc. For: Dec 09 Filed by: DALE MICHAEL D
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/6
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha]
14.0%
2/5 Axogen, Inc. to Present at the Leerink Partners 9th Annual Global Healthcare Conference 10.5%
8/12 Form 4 Axogen, Inc. For: Aug 09 Filed by: Zaderej Karen L. 9.2%
8/16 Form 8-K Axogen, Inc. For: Aug 14 6.8%
6/12 AxoGen, Inc (NASDAQ: AXGN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 6.4%
12/20 Form 4 Axogen, Inc. For: Dec 18 Filed by: Freitag Gregory Gene 5.6%
8/7 AxoGen (AXGN) Investor Presentation - Slideshow [Seeking Alpha] 5.5%
11/23 Edited Transcript of AXGN earnings conference call or presentation 6-Nov-19 9:30pm GMT [Yahoo! Finance News] 5.1%
8/15 Form 4 Axogen, Inc. For: Aug 09 Filed by: Gold Mark Stephen 4.9%
2/14 Form SC 13G/A Axogen, Inc. Filed by: EW Healthcare Partners, L.P. 4.7%
2/5 Axogen, Inc. to Present at the Leerink Partners 9th Annual Global Healthcare Conference 10.5%
8/12 Form 4 Axogen, Inc. For: Aug 09 Filed by: Zaderej Karen L. 9.2%
8/16 Form 8-K Axogen, Inc. For: Aug 14 6.8%
6/12 AxoGen, Inc (NASDAQ: AXGN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 6.4%
12/20 Form 4 Axogen, Inc. For: Dec 18 Filed by: Freitag Gregory Gene 5.6%
8/7 AxoGen (AXGN) Investor Presentation - Slideshow [Seeking Alpha] 5.5%
11/23 Edited Transcript of AXGN earnings conference call or presentation 6-Nov-19 9:30pm GMT [Yahoo! Finance News] 5.1%
8/15 Form 4 Axogen, Inc. For: Aug 09 Filed by: Gold Mark Stephen 4.9%
2/14 Form SC 13G/A Axogen, Inc. Filed by: EW Healthcare Partners, L.P. 4.7%
TOP News Decliners
8/6
AxoGen Inc (AXGN) Q2 2019 Earnings Call Transcript [The Motley Fool]
-29.2%
2/24 Axogen, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results -17.0%
1/13 Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2019 and Provides 2020 Annual Guidance -15.3%
1/3 Form 4 Axogen, Inc. For: Jan 01 Filed by: Rudelius Robert James -11.6%
3/2 Axogen, Inc. to Participate at Upcoming Investor Conferences -8.1%
5/16 Form 4 Axogen, Inc. For: May 13 Filed by: Hansen David K -7.8%
1/17 Form 4 Axogen, Inc. For: Jan 01 Filed by: Zaderej Karen L. -7.6%
4/15 Axogen, Inc. to Report First Quarter 2020 Financial Results and Host Conference Call on May 6, 2020 -6.2%
4/29 Form 4 Axogen, Inc. For: Apr 28 Filed by: DeVinney Erick Wayne -4.9%
12/4 Avance® Nerve Graft Recipient Selected to Ride on Donate Life Rose Parade® Float -4.8%
2/24 Axogen, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results -17.0%
1/13 Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2019 and Provides 2020 Annual Guidance -15.3%
1/3 Form 4 Axogen, Inc. For: Jan 01 Filed by: Rudelius Robert James -11.6%
3/2 Axogen, Inc. to Participate at Upcoming Investor Conferences -8.1%
5/16 Form 4 Axogen, Inc. For: May 13 Filed by: Hansen David K -7.8%
1/17 Form 4 Axogen, Inc. For: Jan 01 Filed by: Zaderej Karen L. -7.6%
4/15 Axogen, Inc. to Report First Quarter 2020 Financial Results and Host Conference Call on May 6, 2020 -6.2%
4/29 Form 4 Axogen, Inc. For: Apr 28 Filed by: DeVinney Erick Wayne -4.9%
12/4 Avance® Nerve Graft Recipient Selected to Ride on Donate Life Rose Parade® Float -4.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: